C12N 2710/10011
Adenoviridae
C12N2710/10011 (Adenoviridae) appears on 2,242 US grants and 3,768 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,242
- Published applications
- 3,768
- Assignees
- 1,257
- Inventors
- 5,428
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 14 | 0 |
| 1997 | 22 | 0 |
| 1998 | 46 | 0 |
| 1999 | 58 | 0 |
| 2000 | 64 | 0 |
| 2001 | 72 | 30 |
| 2002 | 79 | 170 |
| 2003 | 81 | 204 |
| 2004 | 67 | 158 |
| 2005 | 51 | 167 |
| 2006 | 74 | 144 |
| 2007 | 68 | 134 |
| 2008 | 52 | 121 |
| 2009 | 61 | 126 |
| 2010 | 59 | 120 |
| 2011 | 55 | 115 |
| 2012 | 60 | 98 |
| 2013 | 51 | 88 |
| 2014 | 58 | 105 |
| 2015 | 71 | 124 |
| 2016 | 82 | 138 |
| 2017 | 84 | 142 |
| 2018 | 96 | 162 |
| 2019 | 103 | 185 |
| 2020 | 111 | 187 |
| 2021 | 107 | 195 |
| 2022 | 111 | 221 |
| 2023 | 101 | 188 |
| 2024 | 97 | 178 |
| 2025 | 107 | 168 |
| 2026 | 61 | 100 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/10311MastadenovirusIndexing code1,809
- C12N 2710/10041Use of virus, viral particle or viral elements as a vectorIndexing code424
- C12N 2710/10032Use of virus as therapeutic agent, other than vaccineIndexing code78
- C12N 2710/10051Methods of production or purification of viral materialIndexing code75
- C12N 2710/10034Use of virus or viral component as vaccineIndexing code72
- C12N 2710/10021Viruses as suchIndexing code54
- C12N 2710/10211AviadenovirusIndexing code43
- C12N 2710/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code42
All 15 subgroupsShow fewer
- C12N 2710/10071Demonstrated in vivo effectIndexing code41
- C12N 2710/10033Use of viral protein as therapeutic agent other than vaccineIndexing code19
- C12N 2710/10111AtadenovirusIndexing code19
- C12N 2710/10061Methods of inactivation or attenuationIndexing code9
- C12N 2710/10023Virus like particles [vlp]Indexing code8
- C12N 2710/10031Uses of virus other than therapeutic or vaccineIndexing code5
- C12N 2710/10088For redistributionIndexing code0
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Compositions and methods for recombinant parvovirus production15 Sep 2026US 12,735,724 B2Aavnergene Inc.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Expression cassette coding for vascular endothelial growth factor8 Oct 2026US 2026/0308618 A1Cornell University
- Compositions and Methods for Increasing AAV Productivity8 Oct 2026US 2026/0308624 A1Oxford Biomedica (US) LLC
Most cited
By later US patents
- Hybrid adenovirus-AAV virus and methods of use thereof311US 5,871,982 AThe Trustees of the University of Pennsylvania · 1999
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002
- Adenovirus vectors for gene therapy278US 5,585,362 AThe Regents of the University of Michigan · 1996
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996